Circadian regulation influences all phases of drug disposition (ADME) and receptor availability, thereby shaping therapeutic efficacy across time
enthusiasm dramatically outpaces science FDA Category 2 classifications for peptides like Semax reflect absence of FDA-standard evidence, not documented harmsRussian clinical experience suggests reasonable safety, but long-term effects by Western standards remain uncharacterized Established interventionsexercise, Mediterranean diet, sleep optimization, cardiovascular risk management, cognitive engagementhave far more consistent evidence than any peptide for dementia risk reduction For Research Prioritization Compounds meriting continued investigation: GLP-1 Agonists: Prevention trials in preclinical/presymptomatic populations, testing compounds with better brain penetration (dulaglutide, lixisenatide) SS-31/Elamipretide: Cognitive outcomes in mitochondrial disease populations, potential expansion to brain aging indications P21: Phase I human trials to establish safety, pharmacokinetics, and proof-of-mechanism for CNTF-pathway neurogenesis Klotho: Watch for Phase 1 results from Jocasta Neuroscience (expected 2027-2028)
Why Prescribers Trust Town & Country Compounding for Glutathione IV A Compounding-Only Pharmacy PCAB-Accredited (via ACHC) NABP-Accredited tccompound.com 800-850-2101 535 East Crescent Ave, Ramsey, NJ 07446 When it comes to intravenous glutathione, not all compounded preparations are created equal and not all compounding pharmacies are either
Cristina Mutchler Author Cristina Mutchler is an award-winning journalist with more than a decade of experience covering health and wellness content for national outlets
